Photo by nci from unsplash
PET-based staging, PFS24 may not be a robust surrogate endpoint for OS. The improved outcomes in PET-staged patients with early progression may be associated with identification and exclusion of patients… Click to show full abstract
PET-based staging, PFS24 may not be a robust surrogate endpoint for OS. The improved outcomes in PET-staged patients with early progression may be associated with identification and exclusion of patients with transformed disease at time of therapy. Patients with early progression are at risk for early death. In contrast, patients with early progression and no evidence of transformation have an extended OS, suggesting aggressive upfront therapies may not be warranted in these patients.
Keywords:
patients early;
maintenance therapy;
response oriented;
oriented maintenance;
therapy;
early progression
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!